Summary & Overview
HCPCS G8634: Clinician-documented Not Eligible for Osteoporosis Pharmacologic Therapy
HCPCS Level II code G8634 is used when a clinician documents that a patient is not an eligible candidate for pharmacologic therapy for osteoporosis. The code captures the clinical determination that medication-based osteoporosis treatment is inappropriate at the time of evaluation, and it standardizes documentation across ambulatory settings. Nationally, the code supports quality reporting, care coordination, and payer adjudication where treatment appropriateness matters for coverage and patient safety. Key payers relevant to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmark-oriented context about how G8634 is applied in clinical workflows, an overview of payer considerations, and the clinical circumstances that typically accompany a decision not to prescribe osteoporosis pharmacotherapy. The publication also summarizes reporting implications for quality measures and documentation best practices for claims processing where applicable. Data not available in the input is noted where specific payer policies, modifiers, taxonomies, and related ICD-10 pairings would ordinarily be listed.
Billing Code Overview
HCPCS Level II code G8634 documents that the clinician has determined the patient is not an eligible candidate to receive pharmacologic therapy for osteoporosis. This code is used to record a documented clinical decision that pharmacologic treatment for osteoporosis is inappropriate for the patient at the time of assessment.
-
Service type: Clinical assessment and treatment appropriateness determination
-
Typical site of service: Outpatient clinic, physician office, or other ambulatory care settings
Clinical & Coding Specifications
Clinical Context
A typical patient is a woman aged 75 with a history of fragility wrist fracture, chronic renal insufficiency stage 4, and multiple drug intolerances who presents to primary care for osteoporosis management. The clinician documents a thorough review of bone mineral density testing, fracture risk assessment (e.g., FRAX), medication history, and contraindications to pharmacologic therapy. After evaluation, the clinician records that the patient is not an eligible candidate for osteoporosis pharmacologic therapy due to advanced renal impairment with creatinine clearance below safe thresholds for bisphosphonates and denosumab, prior severe adverse reaction to available agents, and limited life expectancy where risks outweigh benefit. The workflow includes chart review, patient interview, assessment of labs (serum creatinine, calcium), review of prior adverse drug events, shared decision-making discussion documented in the medical record, and selection of non-pharmacologic management (fall prevention, calcium/vitamin D as tolerated, physical therapy). The clinician then submits the appropriate HCPCS Level II code G8634 to indicate documented medical reason for non-prescription of osteoporosis pharmacologic therapy, typically billed by primary care physicians, geriatricians, endocrinologists, or nurse practitioners during an office or outpatient visit in a clinic or outpatient primary care setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service |